Wisdom tooth recovery: could these enzyme pills beat standard care?
NCT ID NCT07304882
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study tested whether adding serratiopeptidase or escin to standard painkillers and antibiotics helps people recover better after having a lower wisdom tooth removed. Twenty-four healthy adults were randomly assigned to one of three groups. Researchers measured facial swelling, jaw stiffness, and pain levels over time to see which combination worked best.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- serratiopeptidase and escin (as add-ons to standard antibiotics and painkillers)
- What this could lead to
- If one of these works better, it could give dentists a new option to help patients recover faster after wisdom tooth surgery.
- What could go wrong
- This is a very small study (24 people) and only looks at short-term recovery after one type of surgery. Results may not apply to other procedures or larger groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMPACTED MANDIBULAR THIRD MOLAR EXTRACTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Science and Technology
Sanaa, Sana'a, Yemen
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood clot and laser combo may tame wisdom tooth pain
- Your own blood may be the key to easier wisdom tooth recovery
- Ozone gas may ease pain after wisdom tooth surgery
- No drain, Same-Day discharge? new study tests safer parotid surgery
- Wisdom tooth pain relief: which steroid works best?
- Which eye drop stings less? small study pits flarex against lotemax SM